Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Consolidation with High-Dose Cytarabine in AML
NCT01324063Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 1986
- Primary completion
- Jun 1994
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cytarabine in acute myeloid leukemia (AML) (6 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Disease-Free Survival, Overall Survival and 4 more. Started Nov 1986; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01324063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01324063.